Here are the 10-K annual reports from DiaMedica Therapeutics Inc. (DMAC) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow DMAC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DMAC filings page.
DiaMedica Therapeutics Inc. outlines its strategy as a clinical-stage biopharmaceutical company developing DM199, a recombinant human tissue kallikrein-1, for preeclampsia, fetal growth restriction and acute ischemic stroke. DM199 has U.S. Fast Track designation for stroke and is supported by extensive Asian experience with urinary and porcine KLK1 analogs.
The company highlights interim Phase 2 preeclampsia data from South Africa showing statistically significant blood pressure reductions, improved uterine artery blood flow and no placental transfer signals. In stroke, the global Phase 2/3 ReMEDy2 trial treats patients within 24 hours of symptom onset, targeting the majority of patients who are ineligible for tPA/TNK or mechanical thrombectomy. DiaMedica also describes a broad patent estate around DM199 and DM300, long potential exclusivity, and reliance on Catalent for GMP manufacturing.